Longterm Follow-up After Remote Ischemic Preconditioning for Prevention of Contrast-induced Nephropathy

Impaired Renal Function Clinical Trial

— RenProLong  

Official title:

Remote Preconditioning for Contrast-Induced Acute Kidney Injury: Long-Term Follow up (RenPro Longterm)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01760031
• Other study ID #: RenPro1L
• Status: Active, not recruiting
• Phase: N/A
• First received: December 28, 2012
• Last updated: December 28, 2012
• Start date: July 2012
• Est. completion date: January 2013

Study information

• Verified date: December 2012
• Source: University of Cologne
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Ethics Commission
• Study type: Observational

Clinical Trial Summary

Remote ischemic preconditioning reduces the incidence of contrast-induced acute kidney injury in patients undergoing elective coronary angiography. This study was designed to acquire long-term data of initially randomized patients in the RenPro Trial.

Description:

Data of the RenPro Trial has been already published. In the present study data of longterm follow up are collected.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 81
• Est. completion date: January 2013
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 90 Years
• Eligibility: All patients who participated to the RenPro trial

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Acute Kidney Injury
• Impaired Renal Function
• Renal Insufficiency

Intervention

Other:
• Ischemic preconditioning
Subjects received ischemic preconditioning previous to cardiac catheterization

Locations

Country	Name	City	State
Germany	University of Cologne	Cologne	NRW

Sponsors (1)

Lead Sponsor	Collaborator
University of Cologne

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Er F, Nia AM, Dopp H, Hellmich M, Dahlem KM, Caglayan E, Kubacki T, Benzing T, Erdmann E, Burst V, Gassanov N. Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot RenPro Trial (Renal Protection Trial). Circulat — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MACCE	Major Adverse Cardiac and Cerebrovascular Events (Combined primary endpoint): All-cause mortality, cardiovascular mortality, rehospitalization, stroke, myocardial infarction, hemodialysis	1 Year	Yes
Secondary	Renal function	changes of serum creatinine, eGFR, NGAL and cystatin C compared to baseline in both groups.	1 year	Yes